Improving Response to Hormone Therapy in Breast Cancer: New Targets, New Therapeutic Options

Keyphrases

• Breast Cancer 100%
• New Therapeutics 100%
• Therapeutic Potential 100%
• Hormone Therapy 100%
• New Targets 100%
• Estrogen 66%
• Hormonal Therapy 66%
• Epigenetic Modification 66%
• Everolimus 66%
• Estrogen Receptor 1 (ESR1) 66%
• Treatment Options 33%
• Tumor 33%
• United States 33%
• Disease Progression 33%
• Clinical Trials 33%
• Neutropenia 33%
• Host Immune Response 33%
• Mammalian Target of Rapamycin (mTOR) 33%
• Genetic Modification 33%
• Deprivation 33%
• Growth Signaling 33%
• Dose Reduction 33%
• Growth Factor Receptor Signaling 33%
• Progesterone Receptor 33%
• Fibroblast Growth Factor Receptor 1 (FGFR1) 33%
• All Diseases 33%
• Intracellular Growth 33%
• Tumor Microenvironment 33%
• Recurrent Disease 33%
• Early Disease 33%
• Novel Combinations 33%
• Histone Deacetylase 1 (HDAC1) 33%
• Constitutive Activation 33%
• MTOR Inhibitor 33%
• Disease Stage 33%
• Survival Signaling 33%
• Novel Therapeutic Targets 33%
• Acquired mutations 33%
• Cyclin-dependent Kinase 6 (CDK6) 33%
• Estrogen Receptor-positive Metastatic Breast Cancer 33%
• Resistance Mechanisms 33%
• Palbociclib 33%
• Topical Steroids 33%
• HER2 Amplification 33%
• Stomatitis 33%
• Hormone Receptor-positive Breast Cancer 33%
• Two-agent 33%
• CDK4/6 Inhibitor Palbociclib 33%
• Intracellular Survival 33%
• Toxicity Management 33%
• HER Family Members 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Endocrine Therapy 100%
• Hormone Cancer Therapy 50%
• Hormone Receptor 50%
• Everolimus 50%
• Palbociclib 50%
• Diseases 50%
• Clinical Trial 25%
• Neutropenia 25%
• Progesterone Receptor 25%
• Growth Factor Receptor 25%
• Recurrent Disease 25%
• Disease Exacerbation 25%
• Fibroblast Growth Factor Receptor 25%
• Tumor Microenvironment 25%
• Mammalian Target of Rapamycin Inhibitor 25%
• Cyclin Dependent Kinase 4 25%
• Histone Deacetylase 25%
• Cyclin Dependent Kinase 6 25%
• Topical Corticosteroid 25%
• Acquired Mutation 25%
• Noma 25%

Medicine and Dentistry

• Breast Cancer 100%
• Hormone Therapy 100%
• Hormone Receptor 40%
• Everolimus 40%
• Palbociclib 40%
• Diseases 40%
• Clinical Trial 20%
• Neutropenia 20%
• Immune Response 20%
• Disease Exacerbation 20%
• Progesterone Receptor 20%
• Growth Factor Receptor 20%
• Tumor 20%
• Recurrent Disease 20%
• Histone Deacetylase 20%
• Tumor Microenvironment 20%
• Mammalian Target of Rapamycin Inhibitor 20%
• Mammalian Target of Rapamycin 20%
• Fibroblast Growth Factor Receptor 20%
• Cyclin-Dependent Kinase 4 20%
• Drug Dose Reduction 20%
• Topical Corticosteroid 20%
• Epigenetic Modification 20%
• Cyclin-Dependent Kinase 6 20%
• CDK4/6 Inhibitor 20%
• Protein Kinase B 20%
• Acquired Mutation 20%
• Treatment Option 20%
• Noma 20%